Reducing Fraud and Lowering Barriers to the Production of Drugs in Shortage by Outsourcing Facilities

Food and Drug Administration · HHS

CFDA Numbers

93.103

Award Ceiling

$3.0M

Award Floor

—

Expected Awards

Close Date

—

Section I

How to Apply

View on grants_gov ↗

Program Contact

patrick.johnson@fda.hhs.gov
patrick.johnson@fda.hhs.gov

Section II

Eligibility

Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations Small Businesses For-Profit Organizations (Other than Small Businesses) Local Governments State Governments County Governments City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized) Federal Governments Eligible Agencies of the Federal Government U.S. Territory or Possession Other Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Regional Organizations N/A Foreign Organizations Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Eligible Applicant Types

Section III

Description

The goals of this grant are to better understand the landscape of drug shortage products, including those vulnerable to health fraud, and identify opportunities for outsourcing facilities to meet drug shortage needs to strengthen the supply chain. Funding would also support outsourcing facilities’ research and development of products that mitigate persistent drug shortages to increase supply of critical medications and stabilize the drug supply chain to prevent health fraud.